Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia Recruiting Phase 2 Trials for Dasatinib (DB01254)

IndicationStatusPhase
DBCOND0114145 (Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02689440Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous LeukemiaTreatment